Validation of treatment strategies for enterohaemorrhagic Escherichia coli O104:H4 induced haemolytic uraemic syndrome: case-control study
Top Cited Papers
Open Access
- 19 July 2012
- Vol. 345 (jul19 1), e4565
- https://doi.org/10.1136/bmj.e4565
Abstract
OBJECTIVE: To evaluate the effect of different treatment strategies on enterohaemorrhagic Escherichia coli O104:H4 induced haemolytic uraemic syndrome.DESIGN: Multicentre retrospective case-control study.SETTING: 23 hospitals in northern Germany.PARTICIPANTS: 298 adults with enterohaemorrhagic E coli induced haemolytic uraemic syndrome.MAIN OUTCOME MEASURES: Dialysis, seizures, mechanical ventilation, abdominal surgery owing to perforation of the bowel or bowel necrosis, and death.RESULTS: 160 of the 298 patients (54%) temporarily required dialysis, with only three needing treatment long term. 37 patients (12%) had seizures, 54 (18%) required mechanical ventilation, and 12 (4%) died. No clear benefit was found from use of plasmapheresis or plasmapheresis with glucocorticoids. 67 of the patients were treated with eculizumab, a monoclonal antibody directed against the complement cascade. No short term benefit was detected that could be attributed to this treatment. 52 patients in one centre that used a strategy of aggressive treatment with combined antibiotics had fewer seizures (2% v 15%, P = 0.03), fewer deaths (0% v 5%, p = 0.029), required no abdominal surgery, and excreted E coli for a shorter duration.CONCLUSIONS: Enterohaemorrhagic E coli induced haemolytic uraemic syndrome is a severe self limiting acute condition. Our findings question the benefit of eculizumab and of plasmapheresis with or without glucocorticoids. Patients with established haemolytic uraemic syndrome seemed to benefit from antibiotic treatment and this should be investigated in a controlled trial.This publication has 33 references indexed in Scilit:
- Epidemic Profile of Shiga-Toxin–ProducingEscherichia coliO104:H4 Outbreak in GermanyThe New England Journal of Medicine, 2011
- Characterisation of the Escherichia coli strain associated with an outbreak of haemolytic uraemic syndrome in Germany, 2011: a microbiological studyThe Lancet Infectious Diseases, 2011
- Open-Source Genomic Analysis of Shiga-Toxin–ProducingE. coliO104:H4The New England Journal of Medicine, 2011
- Origins of theE. coliStrain Causing an Outbreak of Hemolytic–Uremic Syndrome in GermanyThe New England Journal of Medicine, 2011
- The 2011 Shiga toxin-producing Escherichia coli O104:H4 German outbreak: a lesson in genomic plasticityClinical Microbiology & Infection, 2011
- Prospective Genomic Characterization of the German Enterohemorrhagic Escherichia coli O104:H4 Outbreak by Rapid Next Generation Sequencing TechnologyPLOS ONE, 2011
- Shiga-toxin-producing Escherichia coli and haemolytic uraemic syndromeThe Lancet, 2005
- Monitoring patients in the community with suspected Escherichia coli O157 infection during a large outbreak in Scotland in 1996Epidemiology and Infection, 2001
- The Central ScotlandEscherichia coliO157:H7 Outbreak: Risk Factors for the Hemolytic Uremic Syndrome and Death among Hospitalized PatientsClinical Infectious Diseases, 2001
- A multistate outbreak of Escherichia coli O157:H7-associated bloody diarrhea and hemolytic uremic syndrome from hamburgers. The Washington experience.1994